ClinicalTrials.gg
CompletedNCT00654095Updated May 21, 2024Results posted

Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)

A Phase 3 interventional study of Ezetimibe and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2007, registered Apr 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
146
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
50th of 97
146 · median 148
Started
2007
with 15 others
Phase 3
50 of 98
1 open now
Registered
44th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 50th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 44th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and atorvastatin in participants with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with hypercholesterolemia who satisfy the following criteria:

    • Participants who have used any of the following 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (hereinafter referred to as "statins") for 4 weeks or longer before the start of the observation period and whose low density lipoprotein (LDL)-cholesterol level during the treatment had not reached lipid management target
    • Age: 20 years of age or older (at the time of obtaining )
    • Sex: both males and females
    • Inpatient/outpatient: Out-patient

Exclusion criteria

Exclusion Criteria:

  • Participants for whom any of the following is applicable:

    • Participants whose fasted triglyceride level measured at the start of the observation period or the treatment period exceeds 500 mg/dL
    • Participants with homozygous familial hypercholesterolemia
    • Participants with creatine phosphokinase (CPK) > 2x (ULN) measured at the start of the observation period or the treatment period.
    • Participants with serious hepatic disorder, or participants with (ALT) or aspartate aminotransferase (AST) > 2x ULN measured at the start of the observation period or the treatment period.
    • Participants with a history of to any ingredient of ezetimibe tablets or atorvastatin tablets
    • Pregnant, nursing women, women who may be pregnant, or participants wishing to be pregnant during the study.
    • Participants who have discontinued use of serum lipid lowering agents for less than 4 weeks at the start of the treatment period (8 weeks in the case of probucol). (However, if the participant had taken a serum lipid lowering agent before the test conducted at the start of the observation period, a period of discontinuation of 27 days, or 55 days in the case of probucol, is allowed.)
    • Participants who are using cyclosporine from after the start of the observation period
    • Participants with a history of ezetimibe use
    • Participants with hyperlipidemia associated with the following diseases:

      • Hypothyroidism
      • Obstructive gall bladder or biliary disease
      • Chronic renal failure
      • Pancreatitis
    • Participants with hyperlipidemia associated with concomitant use of drugs having adverse effect on serum lipids, etc
    • Participants who have received an drug within 4 weeks of the start of the observation period
    • Other participants deemed not appropriate for study entry by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Ezetimibe + Atorvastatin

    Ezetimibe 10 mg + Atorvastatin 20 mg

    Drug: Ezetimibe · Drug: atorvastatin

Interventions

  • Ezetimibe 10 mg once daily

    Also known as: SCH 58235

  • atorvastatin 20 mg once daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events and Adverse Reactions

    An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified. That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered. Any adverse event that was considered treatment-related was considered an adverse reaction.

    Time frame: Throughout 1 year of study

07

Results

Posted Oct 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe + Atorvastatin
Started146
Completed114
Not completed32
Withdrew: Drop in low density lipoprotein (1)2
Withdrew: Elevated triglyceride level (2)1
Withdrew: Elevated alanine aminotransferase (3)1
Withdrew: Adverse event11
Withdrew: Withdrawal by subject5
Withdrew: Elevated alanine aminotransferase (4)7
Withdrew: Adverse reaction did not improve (5)4
Withdrew: Did not meet inclusion criteria1

Outcome measures

PrimaryNumber of Participants With Adverse Events and Adverse Reactions

An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified. That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered. Any adverse event that was considered treatment-related was considered an adverse reaction.

Time frame:
Throughout 1 year of study
Reported as:
Number · Participants
Number of Participants With Adverse Events and Adverse Reactions
ParticipantsEzetimibe + Atorvastatin
Adverse Events141
Adverse Reactions61

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe+Atorvastatin—11/146 (7.5%)132/146 (90.4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventEzetimibe+Atorvastatin
SICK SINUS SYNDROMECardiac disorders1/146
GLAUCOMAEye disorders1/146
RETINAL ARTERY OCCLUSIONEye disorders1/146
GASTROENTERITISInfections and infestations1/146
HUMERUS FRACTUREInjury, poisoning and procedural complications1/146
IN-STENT CORONARY ARTERY RESTENOSISInjury, poisoning and procedural complications1/146
RIB FRACTUREInjury, poisoning and procedural complications1/146
ULNA FRACTUREInjury, poisoning and procedural complications1/146
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/146
LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/146
Most frequent other events
Showing 10 of 26
Most frequent other events
EventEzetimibe+Atorvastatin
NASOPHARYNGITISInfections and infestations53/146
ALANINE AMINOTRANSFERASE INCREASEDInvestigations48/146
C-REACTIVE PROTEIN INCREASEDInvestigations31/146
GAMMA-GLUTAMYLTRANSFERASE INCREASEDInvestigations24/146
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations20/146
BILIRUBIN CONJUGATED INCREASEDInvestigations18/146
UPPER RESPIRATORY TRACT INFLAMMATIONRespiratory, thoracic and mediastinal disorders18/146
MYOGLOBIN BLOOD INCREASEDInvestigations17/146
MYOGLOBIN URINE PRESENTInvestigations17/146
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations16/146

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ezetimibe + Atorvastatin
Number146
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe + Atorvastatin
Female79
Male67
Region of Enrollment
Region of Enrollment(participants)Ezetimibe + Atorvastatin
Japan146
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2007 to primary completion in Jun 2009, 18 months.

Results were first posted in Oct 2010, 1 year 4 months after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 7, 2008
StartActual
Dec 1, 2007
Primary completionActual
Jun 1, 2009
CompletionActual
Jun 1, 2009
Results first posted
Oct 5, 2010
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00654095
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
Dec 1, 2007
Primary completion
Jun 1, 2009
Completion
Jun 1, 2009
Results posted
Oct 5, 2010
Last update
May 21, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Atorvastatin

Start the discussion